Recent 8-K filings for AKBA

• May 7, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  Akebia posts Q1 net loss of $9.1M; Vafseo revenue rises to $15.8M, patients up 60%

  Net loss of $9.1M in Q1 2026 vs net income of $6.1M in Q1 2025; total revenues $53.5M, down from $57.3M.

• February 26, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Akebia Q4 net product revenue $54.3M, full-year 2025 up 49% YoY; Vafseo launch gains traction

  Q4 total revenue $57.6M (FY2025 $236.2M); net loss narrowed to $12.2M Q4 and $5.3M full year.

• January 12, 2026, 6:59 PM ET other material materiality 0.75 positive item 2.02item 7.01item 9.01

  Akebia expects Q4 2025 Vafseo net revenue $5-6M; dosed first patient in praliciguat Phase 2

  Vafseo Q4 net product revenue expected $5-6M (vs. underlying dosing demand $10.5-11.5M) due to $4.5-5M inventory adjustment at USRC.

• December 1, 2025, 6:59 PM ET M&A materiality 0.70 positive item 1.01item 7.01item 8.01item 9.01

  Akebia buys ADX-097 from Q32 Bio for $10M upfront (total up to $582M milestones); plans Phase 2 trials in 2026

  Upfront $7M paid at closing, additional $3M due in 6 months; development milestones up to $94.5M and commercial milestones up to $487.5M, plus tiered royalties from low single to mid-teen %.

• November 10, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Akebia Q3 net income $0.5M; Vafseo revenue $14.3M; DaVita pilot ongoing

  Q3 total revenue $58.8M (up 57% YoY vs $37.4M); net income $0.5M vs net loss $20.0M in Q3 2024.

• October 28, 2025, 7:59 PM ET regulatory materiality 0.85 negative item 7.01item 8.01item 9.01

  Akebia abandons Vafseo broad label pursuit for non-dialysis CKD after FDA alignment failure

  Akebia will not initiate the VALOR trial for vadadustat in late-stage CKD not on dialysis after FDA feedback.

• August 7, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Akebia Q2 2025 net income $0.2M vs loss; Vafseo rev $13.3M, DaVita pilot in 100+ clinics

  Net income $0.2M (vs net loss of $8.6M in Q2 2024); total revenue $62.5M, up 43%.

• May 8, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Akebia posts Q1 2025 net income of $6.1M; Vafseo launch generates $12.0M in net product rev

  Total Q1 2025 net product revenues $55.8M, up 80% YoY; Vafseo contributed $12.0M in first quarter of U.S. launch.

• March 20, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01item 7.01item 8.01item 9.01

  Akebia prices 25M-share public offering at $2.00/share, expects $46.5M net proceeds

  Underwritten public offering of 25M shares at $2.00/share; gross proceeds $50M.

• March 13, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Akebia Q4 net loss $22.8M; expects Vafseo Q1 2025 revenue ~$10-11M

  Total revenues Q4 $46.5M, down 17% YoY; Auryxia net revenue $44.4M vs $53.2M.

• January 13, 2025, 6:59 PM ET other material materiality 0.65 neutral item 7.01item 8.01item 9.01

  Akebia guides cash runway of at least two years, funding Vafseo launch and pipeline

  Expects existing cash and cash from ops to fund current plan for at least two years.

• November 7, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Akebia Q3 2024 net loss $20M; Vafseo launch on track for Jan 2025 with 60% dialysis patient coverage

  Total revenues $37.4M in Q3 2024 vs $42.0M in Q3 2023, driven by Auryxia volume decline.

• October 22, 2024, 7:59 PM ET other material materiality 0.70 positive item 7.01item 9.01

  Akebia signs multi-year supply agreement with leading dialysis org for Vafseo access

  Contract with a leading kidney care provider serving >200,000 patients at thousands of U.S. dialysis centers.

• August 8, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Akebia Q2 2024 net loss narrows to $8.6M; Vafseo launch on track for Jan 2025

  Total revenues $43.6M (down 23% YoY); Auryxia net product rev $41.2M vs $42.2M in Q2 2023.

• July 11, 2024, 7:59 PM ET other material materiality 0.75 neutral item 1.01item 1.02

  Akebia terminates Vafseo license with CSL Vifor, sets royalty payments and buy-down option

  License agreement terminated immediately for business reasons; Akebia regains full U.S. marketing rights for Vafseo.

• May 9, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Akebia Q1 net loss narrows to $18M; Vafseo FDA approved, launch set for Jan 2025

  Total revenues $32.6M (Q1 2024) vs $40.0M (Q1 2023); Auryxia net product revenues $31.0M vs $34.7M.

• March 28, 2024, 7:59 PM ET regulatory materiality 0.85 positive item 7.01item 8.01item 9.01

  Akebia Therapeutics receives FDA approval for Vafseo (vadadustat) for dialysis patients

  FDA approved Vafseo for anemia due to CKD in adults on dialysis ≥3 months; boxed warning for thrombosis risks.

• March 15, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change ×2

  Akebia CFO Ellen Snow to depart March 22; CEO John Butler named interim principal financial officer

  CFO Ellen Snow and company mutually agree on transition; effective March 22, 2024.

• March 14, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Akebia reports Q4 2023 net income $0.6M, Auryxia $53.2M; vadadustat PDUFA Mar 27

  Net income of $0.6M in Q4 2023 vs net loss $6.1M a year ago; full-year net income $51.9M vs loss $94.2M in 2022.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event earnings

9 positive 2 negative 18 neutral

source · AKBA on sec.gov